Cerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027

Benzinga · 3d ago

Previously reported interim Phase 2 data showed a 63% improvement in median overall